Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

NCT03519971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy

NCT04306042 ·Status: UNKNOWN

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

NCT04144582 ·Status: COMPLETED ·Phase: PHASE2

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

NCT03850444 ·Status: COMPLETED ·Phase: PHASE3

A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

NCT04611776 ·Status: WITHDRAWN ·Phase: PHASE2

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

NCT07034391 ·Status: RECRUITING ·Phase: PHASE2

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

NCT07251582 ·Status: RECRUITING ·Phase: PHASE3

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer

NCT04326153 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

NCT07129161 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

NCT04205812 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

NCT06299371 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

NCT05751187 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

NCT04005716 ·Status: COMPLETED ·Phase: PHASE3

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

NCT05599789 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

NCT04379635 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

NCT04194203 ·Status: COMPLETED ·Phase: PHASE3

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

NCT06310915 ·Status: RECRUITING

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

NCT05296278 ·Status: RECRUITING ·Phase: PHASE2

Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC

NCT00321334 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

NCT04728724 ·Status: RECRUITING ·Phase: PHASE2

A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

NCT04023617 ·Status: UNKNOWN ·Phase: PHASE2

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

NCT04393883 ·Status: UNKNOWN ·Phase: NA

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

NCT04316364 ·Status: RECRUITING ·Phase: PHASE3

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

NCT07082179 ·Status: RECRUITING ·Phase: PHASE2

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

NCT03875092 ·Status: COMPLETED ·Phase: PHASE3